- Home
- ME vs PBYI Comparison
ME vs PBYI Comparison
Compare ME & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- PBYI
- Stock Information
- Founded
- ME 2006
- PBYI 2010
- Country
- ME United States
- PBYI United States
- Employees
- ME N/A
- PBYI N/A
- Industry
- ME Precision Instruments
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- PBYI Health Care
- Exchange
- ME Nasdaq
- PBYI Nasdaq
- Market Cap
- ME 168.9M
- PBYI 176.1M
- IPO Year
- ME N/A
- PBYI N/A
- Fundamental
- Price
- ME $0.30
- PBYI $2.32
- Analyst Decision
- ME Hold
- PBYI Strong Buy
- Analyst Count
- ME 1
- PBYI 1
- Target Price
- ME $0.47
- PBYI $7.00
- AVG Volume (30 Days)
- ME 2.6M
- PBYI 393.6K
- Earning Date
- ME 11-06-2024
- PBYI 10-31-2024
- Dividend Yield
- ME N/A
- PBYI N/A
- EPS Growth
- ME N/A
- PBYI N/A
- EPS
- ME N/A
- PBYI 0.18
- Revenue
- ME $199,188,000.00
- PBYI $219,143,000.00
- Revenue This Year
- ME $0.05
- PBYI N/A
- Revenue Next Year
- ME $17.98
- PBYI N/A
- P/E Ratio
- ME N/A
- PBYI $12.75
- Revenue Growth
- ME N/A
- PBYI N/A
- 52 Week Low
- ME $0.30
- PBYI $2.13
- 52 Week High
- ME $1.16
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- ME 34.11
- PBYI 34.73
- Support Level
- ME $0.30
- PBYI $2.23
- Resistance Level
- ME $0.32
- PBYI $2.56
- Average True Range (ATR)
- ME 0.02
- PBYI 0.17
- MACD
- ME 0.00
- PBYI -0.01
- Stochastic Oscillator
- ME 0.00
- PBYI 14.06
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.